Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • NPI Medicare & Medicaid
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.28
    OpenPayerPolicy UpdatesReimbursement/Payment PolicyBCBSNM biomarker testing coverage update | OpenPay…
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - New MexicoPolicy CPCPLABO36

    Biomarker Testing for Multiple Sclerosis and Related Neurologic Diseases

    Customize your policy alerts

    Sign up for Blue Cross Blue Shield - New Mexico Policy CPCPLABO36 alerts

    Get alerted when Policy CPCPLABO36 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines Blue Cross Blue Shield - New Mexico reimbursement criteria for cerebrospinal fluid and serum biomarker testing (including oligoclonal band analysis, AQP4-IgG, MOG-IgG) used in diagnosis of multiple sclerosis, NMOSD, and MOG-EM; applies to providers submitting claims to the Plan.

    Policy Summary
    PayerBlue Cross Blue Shield - New Mexico
    PolicyBiomarker Testing for Multiple Sclerosis and Related Neurologic Diseases
    Policy CodePolicy CPCPLABO36
    Change TypeClarification, Addition, Title revision
    Effective DateSep 26, 2025
    Last ReviewSep 26, 2025
    Next Review Date
    Key ActionSubmit accurate documentation on claims and provide additional documentation upon request; claims are subject to review.
    SourceLink
    POLICY UPDATE CHANGES

    Added CPT/HCPCS code 83884 to the procedure codes list.

    Title changed from 'Serum Biomarker Testing for Multiple Sclerosis and Related Neurologic Diseases' to current title and reimbursement information unchanged.

    Reimbursement criteria for NMOSD/MOG-EM clarified to require that all listed conditions be met for serum AQP4-IgG and MOG-IgG testing to be reimbursable.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    ≥1CSF reimbursable situations
    All criteriaAQP4/MOG serum reimbursement rule
    Not reimbursableOther serum assays
    Not reimbursableOther CSF biomarker tests
    13Document chunks

    Coverage Criteria for Biomarker Testing

    Coverage criteria for biomarker testing

    Reimbursement is conditional and limited to specific clinical scenarios described below.

    CSF oligoclonal band analysis for MS

    • For individuals with atypical clinical, laboratory, or imaging features
    • For individuals belonging to a population in which MS is less common (e.g., children, older individuals)
    • For individuals with an atypical clinically isolated syndrome (including primary progressive or relapsing-remitting courses)
    • When clinical or imaging evidence is insufficient for diagnosis

    Serum AQP4-IgG and MOG-IgG testing for NMOSD/MOG-EM

    • The individual has monophasic or relapsing acute optic neuritis, myelitis, brainstem encephalitis, encephalitis, or any combination thereof
    • Radiological or electrophysiological findings compatible with central nervous system (CNS) demyelination

    • At least one high‑risk feature present

      • Extensive spinal cord lesion or atrophy on MRI, or large confluent T2 brain lesions
      • Belongs to a higher‑risk population (e.g., pediatric)
      • Prominent papilledema, papillitis, or optic disc swelling during acute optic neuritis
      • Histopathology with primary demyelination and intralesional complement and IgG deposits, or prior diagnosis of pattern II MS
      • Neutrophilic CSF pleocytosis
      • Simultaneous bilateral acute optic neuritis

    Other serum assays

    • ELISA, Western blot, immunohistochemistry, or any other serum assays to test for NMOSD or MOG-EM are not reimbursable

    Other CSF biomarker tests

    • All other CSF biomarker tests, including AQP4-IgG or MOG-IgG for diagnosis of MS, NMOSD, or MOG-EM, are not reimbursable

    Default stance

    • In all other situations, serum biomarker tests for multiple sclerosis are not reimbursable

    Procedure and Assay Codes

    Procedure/assay codes listed in policymixed
    83520
    83884
    83916
    84182
    86051
    86052
    86053
    86362
    86363
    88341
    1–10 of 12
    1/2

    Documentation and Claim Review Expectations

    Documentation Required

    Documentation and Claim Review Expectations

    Providers are responsible for submitting accurate and complete documentation for services performed. Claims must be coded using valid, HIPAA-approved code sets and in accordance with industry-standard coding guidelines (for example: Uniform Billing Editor, AMA CPT and CPT Assistant, HCPCS, ICD-10-CM/PCS, NDCs, DRG guidance, CMS National Correct Coding Initiative and CCI edits). Claims are subject to code-edit protocols and may be reviewed for consistency with benefit coverage, provider contract terms, medical policies, clinical payment and coding policies, and automated coding/software logic. Upon request, providers should supply additional supporting documentation to facilitate claim review and adjudication.

    • Submit claims with accurate code combinations from HIPAA-approved code sets (CPT, HCPCS, ICD-10, NDC, etc.).
    • Follow industry standard coding guidance (AMA CPT, Uniform Billing Editor, CMS NCCI/CCI edits, DRG rules).
    • Claims may be reviewed against benefit documents, provider contracts, medical and coding policies, and coding software logic.
    • If requested, promptly provide additional documentation to support the claim.
    • BCBSNM retains discretion to interpret and apply this policy; plan documents and provider contracts govern in case of conflict.

    Plan Definitions and Covered Assays

    Plan reimbursement criteria — lab management reimbursement criteria
    DefinitionPlan reimbursement criteria: Lab management reimbursement criteria implemented by the Plan; not all requirements apply to each product and providers should review Plan documents for eligible coverage.
    ScopeApplies to cerebrospinal fluid (CSF) and serum biomarker testing used in diagnosis of MS, NMOSD, and MOG-EM when specific clinical criteria are met.
    Provider responsibilityProviders are urged to review Plan documents for eligible coverage for services rendered.
    Operational noteNot all requirements apply to each product — check member plan for applicability.
    Covered and non-covered biomarker assays
    Covered assays (may be reimbursable)
    Policy Summary
    PayerBlue Cross Blue Shield - New Mexico
    PolicyBiomarker Testing for Multiple Sclerosis and Related Neurologic Diseases
    Policy CodePolicy CPCPLABO36
    Change TypeClarification, Addition, Title revision
    Effective DateSep 26, 2025
    Last ReviewSep 26, 2025
    Next Review Date
    Key ActionSubmit accurate documentation on claims and provide additional documentation upon request; claims are subject to review.
    SourceLink
    On This Page
    Coverage Criteria for Biomarker TestingProcedure and Assay CodesDocumentation and Claim Review ExpectationsPlan Definitions and Covered Assays
    Severe or frequent episodes of acute myelitis or brainstem encephalitis
  1. Severe visual deficit or blindness in one or both eyes during or after acute optic neuritis
  2. Permanent sphincter and/or erectile disorder after myelitis
  3. Previous diagnosis of acute disseminated encephalomyelitis (ADEM)
    4. CSF and serum oligoclonal band analysis for diagnosis of MS may be reimbursable in specified clinical situations (atypical features, populations where MS is less common, atypical clinically isolated syndrome, or insufficient clinical/imaging evidence).
    Covered assays for NMOSD/MOG-EM (conditional)Serum indirect fluorescence assay or FACS assay for AQP4-IgG and MOG-IgG may be reimbursable when all listed clinical, radiological/electrophysiological, and high‑risk feature criteria are met (e.g., monophasic/relapsing optic neuritis, compatible CNS demyelination findings, and at least one high‑risk feature such as extensive spinal cord lesion, pediatric/high‑risk population, papilledema, histopathology with intralesional complement/IgG, neutrophilic CSF pleocytosis, bilateral optic neuritis, severe/frequent myelitis/brainstem encephalitis, severe visual deficit, permanent sphincter/erectile disorder, or prior ADEM).
    Explicitly non-reimbursable serum assaysELISA, Western blot, immunohistochemistry, or any other serum assays to test for NMOSD or MOG-EM are not reimbursable.
    Non-reimbursable CSF biomarker testsAll other CSF biomarker tests, including AQP4-IgG or MOG-IgG for diagnosis of MS, NMOSD, or MOG-EM, are not reimbursable.
    Default stanceIn all other situations, serum biomarker tests for multiple sclerosis are not reimbursable.